# TB-500 (Thymosin Beta-4): What the Research Shows

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide present in virtually all human and animal cells. One of the most abundant peptides in the human body, Thymosin Beta-4 plays key roles in cellular processes that have made it the subject of significant preclinical research interest.

## What Is Thymosin Beta-4?

Thymosin Beta-4 was first isolated from bovine thymus tissue in 1981. It is encoded by the TMSB4X gene and is found in particularly high concentrations in platelets, wound fluid, and macrophages — cells involved in tissue repair processes. TB-500 refers specifically to a fragment of this peptide that researchers have used in laboratory studies.

## Key Research Areas

### Actin Binding and Cell Migration

The primary known function of Thymosin Beta-4 is its role as a G-actin sequestering protein. By binding to actin monomers, it helps regulate the balance between polymerized (F-actin) and monomeric (G-actin) forms. This function is of significant research interest because actin dynamics are central to cell migration, a process relevant to wound healing and tissue repair research.

### Cardiovascular Research

A number of preclinical studies have examined Thymosin Beta-4 in the context of cardiac tissue. Researchers at the National Institutes of Health and other institutions have investigated the peptide’s potential role in models of cardiac injury and repair, including studies examining cardiomyocyte survival and angiogenesis following ischemic events in animal models.

### Anti-inflammatory Research

Several published studies have documented Thymosin Beta-4’s apparent anti-inflammatory properties in preclinical models. Researchers have noted its influence on inflammatory cytokine cascades and its potential role in modulating inflammatory responses in various tissue types.

## BPC-157 + TB-500: The Research Combination

An area of growing preclinical research interest involves the concurrent administration of BPC-157 and TB-500 in animal models. Some researchers have theorized that the two peptides may have complementary mechanisms, with TB-500 potentially influencing systemic processes while BPC-157 acts more locally. However, this remains an emerging area of research with limited published data.

## Research Status

Thymosin Beta-4 has advanced further in the clinical research pipeline than many peptides. RegeneRx Biopharmaceuticals has conducted clinical trials investigating a related compound (RGN-352) for cardiac applications. However, TB-500 itself remains available for research purposes only and has not received regulatory approval for therapeutic use.

Related reading: our [Inflammation and Tissue Repair Research Compounds](https://portaltowellness.net/immune-kit/) overview and the [Repair-Pathway Research Compound Index](https://portaltowellness.net/tissue-repair-compound-index/) .

*Disclaimer: This article is for educational purposes only. TB-500 is a research chemical not approved for human use. All information pertains to preclinical and limited clinical research findings.*

---

Source: https://portaltowellness.net/tb-500-thymosin-beta-4-research-overview/
Research use only. Terms: https://portaltowellness.net/research-use-only/